The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,…
Claudia Valverde
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…
In recognition of multidisciplinary integrated cancer care, translational and clinical cancer research of excellence at the Vall d’Hebron University Hospital…
In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…
